Accessibility Menu
 
Tenaya Therapeutics logo

Tenaya Therapeutics

(NASDAQ) TNYA

Current Price$0.62
Market Cap$134.54M
Since IPO (2021)-96%
5 YearN/A
1 Year-3%
1 Month+10%

Tenaya Therapeutics Financials at a Glance

Market Cap

$134.54M

Revenue (TTM)

$0.00

Net Income (TTM)

$90.60M

EPS (TTM)

$-0.63

P/E Ratio

-0.99

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.62

Volume

40,951

Open

$0.67

Previous Close

$0.62

Daily Range

$0.62 - $0.67

52-Week Range

$0.36 - $2.35

TNYA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tenaya Therapeutics

Industry

Biotechnology

Employees

70

CEO

Faraz Ali, MBA

Headquarters

South San Francisco, CA 94080, US

TNYA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-84%

Return on Capital

-71%

Return on Assets

-62%

Earnings Yield

-1.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.54M

Shares Outstanding

217.00M

Volume

40.95K

Short Interest

0.00%

Avg. Volume

4.45M

Financials (TTM)

Gross Profit

$8.44M

Operating Income

$93.33M

EBITDA

$84.89M

Operating Cash Flow

$68.26M

Capital Expenditure

$618.00K

Free Cash Flow

$68.88M

Cash & ST Invst.

$100.55M

Total Debt

$10.83M

Tenaya Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$3.95M

N/A

Gross Margin

0.00%

N/A

Market Cap

$134.54M

N/A

Market Cap/Employee

$1.39M

N/A

Employees

97

N/A

Net Income

$20.18M

+15.4%

EBITDA

$18.95M

+16.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$89.72M

+87.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.81M

-27.9%

Short Term Debt

$3.02M

+8.7%

Return on Assets

-61.66%

N/A

Return on Invested Capital

-70.98%

N/A

Free Cash Flow

$14.01M

+24.7%

Operating Cash Flow

$13.94M

+24.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRBUCaribou Biosciences, Inc.
$1.72-3.37%
PRLDPrelude Therapeutics Incorporated
$3.07+0.66%
IMRXImmuneering Corporation
$4.88-1.61%
HUMAHumacyte, Inc.
$0.57-14.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.13-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$89.42+0.02%
IBITiShares Bitcoin Trust
$37.68+0.01%

Questions About TNYA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.